OBJECTIVE: To probe into the effect of liraglutide on serum Klotho （KL）

secreted frizzled-related protein-5 （SFRP5） and adipocytokines in patients with obese type 2 diabetes. METHODS: Totally 86 patients with obese type 2 diabetes admitted into the First People’s Hospital of Tianmen from Jan. 2017 to Jan. 2019 were selected and divided into group A （43 cases） and group B （43 cases） via random number table. Group A was given metformin orally

group B was given subcutaneous injection of liraglutide

both groups were treated continuously for 16 weeks. The clinical efficacy and incidences of adverse drug reactions of two groups

the body mass index （BMI）

glycosylated hemoglobin （HbA1c）

fasting blood-glucose （FBG）

glucagon

abdominal fat area （VA）

serum KL

SERP5

inflammatory factors[interleukin-6 （IL-6）

tumor necrosis factor α （TNF-α） ]and adipocytokines （adiponectin

leptin） levels before and after treatment were observed. RESULTS: The total effective rate of group B was 93. 02% （40/43）

which was significantly higher than that of group A （76. 74%

33/43）

with statistically significant difference （P < 0. 05）. After16-week treatment

the BMI

HbA1c

FBG and glucagon levels of both groups had been significantly decreased

and those of group B were significantly lower than group A

with statistically significant differences （P<0. 05）. After 16-week treatment

the VA

IL-6

TNF-α and leptin levels of both groups had been significantly decreased

the IL-6

TNF-α and leptin levels of group B were significantly lower than those of group A

with statistically significant differences （P <0. 05）

there was no statistical significance in difference in VA levels between two groups （P>0. 05）; the adiponectin levels of both groups had been significantly increased

and that of group B was significantly higher than group A

with statistically significant differences （P<0. 05）. After 16-week treatment

the serum KL and SFRP5 levels of both groups had been significantly increased

and those of group B were significantly higher than group A

with statistically significant differences （P < 0. 05）. During treatment

the incidence of adverse drug reactions of group B was11. 63% （5/43）

which was significantly lower than that of group A （34. 88%

15/43）

with statistically significant difference （χ2= 6. 52

P = 0. 01）. CONCLUSIONS: Liraglutide can achieve the purpose of lowering blood glucose by inhibiting the glucagon level

which has more significant effect than that of metformin. Liraglutide can reduce the abdominal fat content and BMI of obese type 2 diabetes patients

regulate body adipocytokines and expression levels of KL and SFRP5.